Enhanced oral bioavailability and antiasthmatic efficacy of curcumin using redispersible dry emulsion

Bio-Medical Materials and Engineering

Volumn 24, Issue 1, 2014, Pages 917-930

  Jang, Dong Jin ^a   Kim, Sung Tae ^b   Oh, Euichaul ^a   Lee, Kooyeon ^c  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c Kangwon National University   (South Korea)

Author keywords

antiasthmatic efficacy; bioavailability; Curcumin; dry emulsion; functional food; poorly water soluble

Indexed keywords

ANTIASTHMATIC EFFICACY; BIOAVAILABILITY; CURCUMIN; FUNCTIONAL FOODS; POORLY WATER-SOLUBLE;

BIOCHEMISTRY; BIOTECHNOLOGY; EMULSIFICATION; MEDICINE; OILS AND FATS; SOLUBILITY;

EMULSIONS;

ALPHA TOCOPHEROL; ARACHIS OIL; CASTOR OIL; CORN OIL; COTTON SEED OIL; CURCUMIN; DEXTRIN; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LABRAFAC CC; MINERAL OIL; MYRISTIC ACID ISOPROPYL ESTER; OIL; OLIVE OIL; PEGLICOL 5 OLEATE; PLUROL OLEIQUE CC 497; SESAME SEED OIL; SORBITAN OLEATE; SOYBEAN OIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIASTHMATIC ACTIVITY; AREA UNDER THE CURVE; ASTHMA; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; FEMALE; FUNCTIONAL FOOD; IN VITRO STUDY; INFANT; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; RESPIRATORY TRACT ALLERGY; SPRAY DRYING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTIASTHMATIC EFFICACY; BIOAVAILABILITY; CURCUMIN; DRY EMULSION; FUNCTIONAL FOOD; POORLY WATER-SOLUBLE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; ASTHMA; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CURCUMIN; CYTOKINES; EMULSIONS; FEMALE; IMMUNOGLOBULIN E; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-5; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; MODELS, STATISTICAL; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; WATER;

EID: 84891096098     PISSN: 09592989     EISSN: None     Source Type: Journal    
DOI: 10.3233/BME-130886     Document Type: Conference Paper

References (77)

1. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: Problems and promises. Mol Pharm 4:807-818.
2. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. 2008. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci 65:1631-1652.
3. Lee JH, Kim JW, Ko NY, Mun SH, Her E, Kim BK, Choi WS. 2008. Curcumin, a constituent of curry, suppresses IgEmediated allergic response and mast cell activation at the level of Syk. J Allergy ClinImmun 121:1225-1231.
4. Chainani-Wu N. 2003. Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). J Alternative Compl Med 9:161-168.
5. Suzuki M, Nakamura T, Iyoki S, Fujiwara A, Watanabe Y, Mohri K, Yano S. 2005. Elucidation of anti-allergic activities of curcumin-related compounds with a special reference to their anti-oxidative activities. BiolPharmaceut Bull 28:1438-1443.
6. Chung SH, Choi SH, Choi JA, Chuck RS, Joo CK. 2012. Curcumin suppresses ovalbumin-induced allergic conjunctivitis. Mol Vis 18:1966-1972.
7. Clark CE, Arnold E, Lasserson TJ, Wu T. 2010. Herbal interventions for chronic asthma in adults and children: A systematic review and meta-analysis. Prim Care Respir J19:307-314.
8. Kurup VP, Barrios CS. 2008. Immunomodulatory effects of curcumin in allergy. MolNutr Food Res 52:1031-1039.
9. Rahimi R, Mozaffari S, Abdollahi M. 2009. On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig Dis Sci 54:471-480.
10. Xie X, Tao Q, Zou Y, Zhang F, Guo M, Wang Y, Wang H, Zhou Q, Yu S. 2011. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: Characterizations and mechanisms. J Agr Food Chem 59:9280-9289.
11. Yu H, Huang Q. 2012. Improving the oral bioavailability of curcumin using novelorganogel-based nanoemulsions. J Agric Food Chem 60:5373-5379.
12. Wang X, Jiang Y, Wang YW, Huang MT, Ho CT, Huang Q. 2008. Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions. Food Chemistry108:419-424.
13. Jang DJ, Jeong EJ, Lee HM, Kim BC, Lim SJ, Kim CK. 2006. Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. Eur J Pharmaceut Sci 28:405-411.
14. Floyd AG. 1999. Top ten considerations in the development of parenteral emulsions. Pharm SciTechnolTo2:134-143.
15. Welin-Berger K, Bergenstahl B. 2000. Inhibition of Ostwald ripening in local anesthetic emulsions by using hydrophobic excipients in the disperse phase. Int J Pharm200:249-260.
16. Vyas SP, Jain CP, Kaushik A, Dixit VK. 1992. Preparation and characterization of griseofulvin dry emulsion. Pharmazie47: 463-464.
17. Yin YM, Cui FD, Kim JS, Choi MK, Choi BC, Chung SJ, Kim DD. 2009. Preparation, characterization and in vitro intestinal absorption of a dry emulsion formulation containing atorvastatin calcium. Drug Deliv16:30-36.
18. Braman SS. 2006. The global burden of asthma. CHEST Journal 130:1-suppl, 4S-12S.
19. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. 2000. Asthma from bronchoconstriction to airways inflammation and remodeling. Am J RespCrit Care 161:1720-1745.
20. Rogers DF. 2004. Airway mucus hypersecretion in asthma: An undervalued pathology CurrOpinPharmacol 4:241-250.
21. Hauber HP, Foley SC, Hamid Q. 2006. Mucin overproduction in chronic inflammatory lung disease. Can Respir J 13:327-335.
22. Barnes PJ. 1999. Therapeutic strategies for allergic diseases. Nature 402:31-38.
23. Barnes PJ. 2001. Th2 cytokines and asthma: An introduction. Respir Res2:64-65.
24. Seong JH, Lee KM, Kim ST, Jin SE, Kim CK. 2006. Polyethylenimine-based antisense oligodeoxynucleotides of IL-4 suppress the production of IL-4 in a murine model of airway inflammation. J Gene Med 8:314-323.
25. Renauld JC. 2001. New insights into the role of cytokines in asthma. J ClinPathol54:577-589.
26. Ray A, Cohn L. 1999. Th2 cells and GATA-3 in asthma: New insights into the regulation of airway inflammation. J Clin Invest 104:985-993.
27. Mazzarella G, Bianco A, Catena E, De Palma R, Abbate GF. 2000. Th1/Th2 lymphocyte polarization in asthma. Allergy55: 6-9.
28. Baena-Cagnani CE, Berger WE, DuBuske LM, Gurne SE, Stryszak P, Lorber R, Danzig M. 2003. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of -2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Imm 130:307-313.
29. Chauhan B, Patel M, Padh H, Nivsarkar M. 2008. Combination therapeutic approach for asthma and allergic rhinitis. Cur ClinPharmacol 3:185-197.
30. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Fahy JV. 2007. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J RespCrit Care 175:783-790.
31. Matsuo Y, Ishihara T, Ishizaki J, Miyamoto KI, Higaki M, Yamashita N. 2009. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol260:33-38.
32. Abramson MJ, Walters J, Walters EH. 2003. Adverse Effects of -Agonists. Am J Respir Med 2:287-297.
33. Adcock IM, Caramori G, Chung KF. 2008. New targets for drug development in asthma. The Lancet 372:1073-1087.
34. Simons F. 2003. H1-antihistamines: More relevant than ever in the treatment of allergic disorders. J allergy ClinImmun112: S42-S52.
35. Li XM. 2007. Traditional Chinese herbal remedies for asthma and food allergy. J Allergy ClinImmunol120:25-31.
36. Rowe RC, Sheskey PJ, Owen SC. Handbook of pharmaceutical excipients. 2003. London: Pharmaceutical press. 651- 653.
37. Date AA, Nagarsenker MS. 2007. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoximeproxetil. Int J Pharm329:166-172.
38. Piao HM, Balakrishnan P, Cho HJ, Kim H, Kim YS, Chung SJ, Kim DD. 2010. Preparation and evaluation of fexofenadine microemulsions for intranasal delivery. Int J Pharm395:309-316.
39. Park YN, Lee YJ, Choi JH, Jin M, Yang JH, Li Y, Lee J, Li X, Kim KJ, Son JK, Chang HW, Kim JY, LEE E. 2011. Alleviation of OVA-induced airway inflammation by flowers of Inula japonica in a murine model of asthma. BiosciBiotechnolBiochem75: 871-876.
40. Bryce PJ, Geha R, Oettgen HC. 2003. Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. J Allergy ClinImmunol112:149-58.
41. Edwan JH, Perry G, Talmadge JE, Agrawal DK. 2004. Flt-3 ligand reverses late allergic response and airway hyperresponsiveness in a mouse model of allergic inflammation. J Immunol172:5016-5023.
42. Zhang J, Gao Y, Qian S, Liu X, Zu H. 2011. Physicochemical and pharmacokinetic characterization of a spray-dried malotilate emulsion. Int J Pharm414:186-192.
43. Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H. 1992. Improvement of photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion. Int J Pharm 86:25-33.
44. Jang DJ, Jeong EJ, Lee HM, Kim BC, Lim SJ, Kim CK. 2006. Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. Eur J Pharmaceut Sci 28:405-411.
45. Floyd AG. 1999. Top ten considerations in the development of parenteral emulsions. Pharm SciTechnolTo2:134-143.
46. Welin-Berger K, Bergenstahl B. 2000. Inhibition of Ostwald ripening in local anesthetic emulsions by using hydrophobic excipients in the disperse phase. Int J Pharm200:249-260.
47. Vyas SP, Jain CP, Kaushik A, Dixit VK. 1992. Preparation and characterization of griseofulvin dry emulsion. Pharmazie47: 463-464.
48. Yin YM, Cui FD, Kim JS, Choi MK, Choi BC, Chung SJ, Kim DD. 2009. Preparation, characterization and in vitro intestinal absorption of a dry emulsion formulation containing atorvastatin calcium. Drug Deliv16:30-36.
49. Braman SS. 2006. The global burden of asthma. CHEST Journal 130:1-suppl, 4S-12S.
50. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. 2000. Asthma from bronchoconstriction to airways inflammation and remodeling. Am J RespCrit Care 161:1720-1745.
51. Rogers DF. 2004. Airway mucus hypersecretion in asthma: An undervalued pathology CurrOpinPharmacol 4:241-250.
52. Hauber HP, Foley SC, Hamid Q. 2006. Mucin overproduction in chronic inflammatory lung disease. Can Respir J 13:327-335.
53. Barnes PJ. 1999. Therapeutic strategies for allergic diseases. Nature 402:31-38.
54. Barnes PJ. 2001. Th2 cytokines and asthma: An introduction. Respir Res2:64-65.
55. Seong JH, Lee KM, Kim ST, Jin SE, Kim CK. 2006. Polyethylenimine-based antisense oligodeoxynucleotides of IL-4 suppress the production of IL-4 in a murine model of airway inflammation. J Gene Med 8:314-323.
56. Renauld JC. 2001. New insights into the role of cytokines in asthma. J ClinPathol54:577-589.
57. Ray A, Cohn L. 1999. Th2 cells and GATA-3 in asthma: New insights into the regulation of airway inflammation. J Clin Invest 104:985-993.
58. Mazzarella G, Bianco A, Catena E, De Palma R, Abbate GF. 2000. Th1/Th2 lymphocyte polarization in asthma. Allergy55: 6-9.
59. Baena-Cagnani CE, Berger WE, DuBuske LM, Gurne SE, Stryszak P, Lorber R, Danzig M. 2003. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of -2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Imm 130:307-313.
60. Chauhan B, Patel M, Padh H, Nivsarkar M. 2008. Combination therapeutic approach for asthma and allergic rhinitis. Cur ClinPharmacol 3:185-197.
61. Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Fahy JV. 2007. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J RespCrit Care 175:783-790.
62. Matsuo Y, Ishihara T, Ishizaki J, Miyamoto KI, Higaki M, Yamashita N. 2009. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol260:33-38.
63. Abramson MJ, Walters J, Walters EH. 2003. Adverse Effects of -Agonists. Am J Respir Med 2:287-297.
64. Adcock IM, Caramori G, Chung KF. 2008. New targets for drug development in asthma. The Lancet 372:1073-1087.
65. Simons F. 2003. H1-antihistamines: More relevant than ever in the treatment of allergic disorders. J allergy ClinImmun112: S42-S52.
66. Li XM. 2007. Traditional Chinese herbal remedies for asthma and food allergy. J Allergy ClinImmunol120:25-31.
67. Rowe RC, Sheskey PJ, Owen SC. Handbook of pharmaceutical excipients. 2003. London: Pharmaceutical press. 651- 653.
68. Date AA, Nagarsenker MS. 2007. Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoximeproxetil. Int J Pharm329:166-172.
69. Piao HM, Balakrishnan P, Cho HJ, Kim H, Kim YS, Chung SJ, Kim DD. 2010. Preparation and evaluation of fexofenadine microemulsions for intranasal delivery. Int J Pharm395:309-316.
70. Park YN, Lee YJ, Choi JH, Jin M, Yang JH, Li Y, Lee J, Li X, Kim KJ, Son JK, Chang HW, Kim JY, LEE E. 2011. Alleviation of OVA-induced airway inflammation by flowers of Inula japonica in a murine model of asthma. BiosciBiotechnolBiochem75: 871-876.
71. Bryce PJ, Geha R, Oettgen HC. 2003. Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. J Allergy ClinImmunol112:149-58.
72. Edwan JH, Perry G, Talmadge JE, Agrawal DK. 2004. Flt-3 ligand reverses late allergic response and airway hyperresponsiveness in a mouse model of allergic inflammation. J Immunol172:5016-5023.
73. Zhang J, Gao Y, Qian S, Liu X, Zu H. 2011. Physicochemical and pharmacokinetic characterization of a spray-dried malotilate emulsion. Int J Pharm414:186-192.
74. Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H. 1992. Improvement of photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion. Int J Pharm 86:25-33. D. -J. Jang et al. /Enhanced oral bioavailability and antiasthmatic efficacy of CUR using redispersible DE 9299
75. Heinzelmann K, Franke K. 1999. Using freezing and drying techniques of emulsions for the microencapsulation of fish oil to improve oxidation stability. Colloids Surf. B 12:223-229.
76. Dollo G, Le Corre P, Guerin A, Chevanne F, Burgot JL, Leverge R. 2003. Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur J Pharm Sci 19:273-280.
77. Georas SN, Guo J, De Fanis U, Casolaro V. 2005. T-helper cell type-2 regulation in allergic disease. EurRespir J26:1119-1137.